McDermott Advises Genkyotex on its Capital Increase with Preferential Shareholders Subscription Rights
The international law firm McDermott Will & Emery assisted Genkyotex, a biopharmaceutical company and the leader in NOX therapies listed on the regulated markets of Euronext Paris and Euronext Brussels, on its capital increase with preferential shareholders subscription rights which was realized on February 10, 2020.
The €4,9 million raised in the public offering are intended to primarily provide the Genkyotex with additional resources to continue, over the next 12 months, the clinical development of its lead product candidate, setanaxib, in multiple fibrotic indications including primary biliary cholangitis (PBC, an orphan fibrotic disorder), idiopathic pulmonary fibrosis (IPF) and diabetic kidney disease.
McDermott Will & Emery advised Genkyotex with a team led in Paris by David Revcolevschi (Partner, capital markets/corporate), together with Stephan de Groër (associate, corporate).
Gilbert Dupont acted as Lead Manager and Bookrunner in the offering.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With more than 20 locations on three continents, our team works seamlessly across practices, industries and geographies to deliver highly effective—and often unexpected—solutions that propel success. More than 1,100 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.